Developer of screening technologies intended to reduce the incidence of cancer. The company's technologies are based on ultra-deep gene sequencing technology, bioinformatics analysis and big data analysis which helps in detecting cancer in precancerous lesions or at the early-stage, providing patients with increased chances of survival and reduced mortality rates.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC (Series A) | 01-Nov-2018 | $7.23M | 000.00 | Completed | Startup | |
2. Early Stage VC | 01-Jan-2017 | 00.000 | 00.000 | Completed | Startup | |
1. Angel (individual) | 01-Jan-2016 | $1.55M | $1.55M | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Chaoyu Liu Ph.D | Chief Executive Officer | ||
Peng Chen | Chief Financial Officer | ||
Chuanbo Xu Ph.D | Chief Medical Officer |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
AMER International Group | Corporation | Minority | 000 0000 | 000000 0 | |
Qianjiang Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
ASBV China | Venture Capital | Minority | 000 0000 | 000000 0 |